Key result
Zinc supplementation prevents diabetes-induced cardiac dysfunction and fibrosis in mice via increased cardiac metallothionein.
Why the study?
Following findings that transgenic mice overexpressing cardiac-specific metallothionein are resistant to diabetic cardiomyopathy, this study explored whether zinc supplementation protects against diabetic cardiomyopathy via cardiac metallothionein induction.
Does zinc supplementation prevent diabetic cardiomyopathy through cardiac metallothionein induction in mice?
Does zinc supplementation prevent diabetic cardiomyopathy through cardiac metallothionein induction in mice?
Zinc supplementation prevents diabetic cardiomyopathy in mice predominantly through the induction of cardiac metallothionein.
Answers are grounded in this paper and cite their sources.
Zinc supplementation may merit further animal testing in diabetic cardiomyopathy; leaves open human translation of MT induction.
BACKGROUND: Our previous studies showed that transgenic mice that overexpress cardiac-specific metallothionein (MT) are highly resistant to diabetes-induced cardiomyopathy. Zinc is the major metal that binds to MT under physiological conditions and is a potent inducer of MT. The present study therefore explored whether zinc supplementation can protect against diabetic cardiomyopathy through cardiac MT induction. METHODS AND RESULTS: Diabetes was induced in mice (C57BL/6J strain) by a single injection of streptozotocin. Half were supplemented intraperitoneally with zinc sulfate (5 mg/kg) every other day for 3 months. After zinc supplementation, mice were maintained for 3 more months and then examined for cardiomyopathy by functional and morphological analysis. Significant increases in cardiac morphological impairment, fibrosis, and dysfunction were observed in diabetic mice but not in diabetic mice supplemented with zinc. Zinc supplementation also induced a significant increase in cardiac MT expression. The role of MT in cardiac protection by zinc supplementation was examined in cultured cardiac cells that were directly exposed to high levels of glucose (HG) and free fatty acid (FFA) (palmitate), treatment that mimics diabetic conditions. Cell survival rate was significantly decreased for cells exposed to HG/FFA but did not change for cells exposed to HG/FFA and pretreated with zinc or low-dose cadmium, each of which induces significant MT synthesis. When MT expression was silenced with the use of MT small-interfering RNA, the preventive effect of pretreatment with zinc or low-dose cadmium was abolished. CONCLUSIONS: These results suggest that the prevention of diabetic cardiomyopathy by zinc supplementation is predominantly mediated by an increase in cardiac MT.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2006) studied Diabetic cardiomyopathy. Zinc supplementation (zinc sulfate) vs. No zinc supplementation was evaluated on Cardiac morphological impairment, fibrosis, and dysfunction. Zinc supplementation prevented diabetes-induced cardiac morphological impairment, fibrosis, and dysfunction in mice, an effect predominantly mediated by an increase in cardiac metallothionein.
Synapse has enriched 10 related papers. Consider them for comparative context: